Emerging treatments

A Phase Ib Study of the combination of the Aurora Kinase Inhibitor Alisertib (MLN8237) and Bortezomib in Relapsed Multiple Myeloma. Rosenthal A et al. Br J Haematol. 2015 Sep 25. doi: 10.1111/bjh.13765. [Epub ahead of print]. Carfilzomib, pomalidomide, and dexamethasone (CPD) in patients with relapsed and/or refractory multiple myeloma. Shah JJ et al. Blood. 2015 Sep 17. pii: blood-2015-05-643320. [Epub ahead of print].…

Biology and genetics

Epigenetic silencing of a long non-coding RNA KIAA0495 in multiple myeloma. Wong KY et al. Mol Cancer. 2015 Sep 26;14(1):175. 3D tissue-engineered bone marrow as a novel model to study pathophysiology and drug resistance in multiple myeloma. de la Puente P et al. Biomaterials. 2015 Sep 12;73:70-84. doi: 10.1016/j.biomaterials.2015.09.017. [Epub ahead of print] Transcriptional dysregulation of the deleted in colorectal carcinoma gene in multiple…

General

Myeloma escape from immunity: an “inside” job. Rapoport AP. Blood. 2015 Sep 17;126(12):1401-3. doi: 10.1182/blood-2015-07-659490. Antibody based immunotherapy for multiple myeloma: It’s about time. Sher T et al, Leuk Lymphoma. 2015 Sep 16:1-17. [Epub ahead of print]. Immunotherapy for Multiple Myeloma, Past, Present, and Future: Monoclonal Antibodies, Vaccines, and Cellular Therapies. Karp Leaf R et al. Curr Hematol Malig Rep. 2015 Sep 4. [Epub ahead of…

Complications of myeloma and its treatments

Early Surgical Occipito-Cervical Stabilization for Plasma Cell Neoplasms at the Cranio-Cervical Junction – Systematic Review and Proposal of a Treatment Algorithm. Ahmadi SA et al. Spine J. 2015 Sep 24. pii: S1529-9430(15)01442-4. doi: 10.1016/j.spinee.2015.09.032. [Epub ahead of print]. Pathologic sternal involvement is a potential risk factor for severe sagittal plane deformity in multiple myelomawith concomitant thoracic fractures. Butler JS et…

Current treatments

Cyclophosphamide plus granulocyte-colony stimulating factor for hematopoietic stem cell mobilization in patients with multiple myeloma. Lin TL et al. J Clin Apher. 2015 Sep 5. doi: 10.1002/jca.21421. [Epub ahead of print]. Plerixafor in combination with granulocyte-colony-stimulating factor after chemotherapy increases mobilization efficiency in patients with lymphoma or myeloma: results of a Phase II clinical trial. Jagirdar N et al. Transfusion. 2015 Sep 2.…

Diagnostic tests and prognostic indicators

IgD multiple myeloma: Clinical, biological features and prognostic value of the serum free light chain assay. Djidjik R et al. Pathol Biol (Paris). 2015 Aug 17. pii: S0369-8114(15)00057-7. doi: 10.1016/j.patbio.2015.06.002. [Epub ahead of print]. Patient dose evaluation for the whole-body low-dose multidetector CT (WBLDMDCT) skeleton study in multiple myeloma (MM). Cretti F et al. Radiol Med. 2015 Aug 19. [Epub ahead of print]. Clinical…

Related conditions

Lenalidomide is safe and active in waldenström macroglobulinemia. Fouquet G et al. Am J Hematol. 2015 Aug 18. doi: 10.1002/ajh.24175. [Epub ahead of print]. Molecular Classification and Pharmacogenetics of Primary Plasma Cell Leukemia: An Initial Approach toward Precision Medicine. Simeon V et al. Int J Mol Sci. 2015 Jul 30;16(8):17514-34. doi: 10.3390/ijms160817514. Treatment of Immunoglobulin Light Chain Amyloidosis: Mayo Stratification of Myeloma and…